Jonathan D Diedrich1,2, Mackenzie K Herroon1, Erandi Rajagurubandara1, Izabela Podgorski3,4. 1. Department of Pharmacology, Wayne State University School of Medicine, 540 E. Canfield, Rm 6304, Detroit, MI, 48201, USA. 2. Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA. 3. Department of Pharmacology, Wayne State University School of Medicine, 540 E. Canfield, Rm 6304, Detroit, MI, 48201, USA. ipodgors@med.wayne.edu. 4. Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA. ipodgors@med.wayne.edu.
Abstract
PURPOSE OF REVIEW: Bone marrow adipocytes have emerged in recent years as key contributors to metastatic progression in bone. In this review, we focus specifically on their role as the suppliers of lipids and discuss pro-survival pathways that are closely linked to lipid metabolism, affected by the adipocyte-tumor cell interactions, and likely impacting the ability of the tumor cell to thrive in bone marrow space and evade therapy. RECENT FINDINGS: The combined in silico, pre-clinical, and clinical evidence shows that in adipocyte-rich tissues such as bone marrow, tumor cells rely on exogenous lipids for regulation of cellular energetics and adaptation to harsh metabolic conditions of the metastatic niche. Adipocyte-supplied lipids have a potential to alter the cell's metabolic decisions by regulating glycolysis and respiration, fatty acid oxidation, lipid desaturation, and PPAR signaling. The downstream effects of lipid signaling on mitochondrial homeostasis ultimately control life vs. death decisions, providing a mechanism for gaining survival advantage and reduced sensitivity to treatment. There is a need for future research directed towards identifying the key metabolic and signaling pathways that regulate tumor dependence on exogenous lipids and consequently drive the pro-survival behavior in the bone marrow niche.
PURPOSE OF REVIEW: Bone marrow adipocytes have emerged in recent years as key contributors to metastatic progression in bone. In this review, we focus specifically on their role as the suppliers of lipids and discuss pro-survival pathways that are closely linked to lipid metabolism, affected by the adipocyte-tumor cell interactions, and likely impacting the ability of the tumor cell to thrive in bone marrow space and evade therapy. RECENT FINDINGS: The combined in silico, pre-clinical, and clinical evidence shows that in adipocyte-rich tissues such as bone marrow, tumor cells rely on exogenous lipids for regulation of cellular energetics and adaptation to harsh metabolic conditions of the metastatic niche. Adipocyte-supplied lipids have a potential to alter the cell's metabolic decisions by regulating glycolysis and respiration, fatty acid oxidation, lipid desaturation, and PPAR signaling. The downstream effects of lipid signaling on mitochondrial homeostasis ultimately control life vs. death decisions, providing a mechanism for gaining survival advantage and reduced sensitivity to treatment. There is a need for future research directed towards identifying the key metabolic and signaling pathways that regulate tumor dependence on exogenous lipids and consequently drive the pro-survival behavior in the bone marrow niche.
Entities:
Keywords:
Apoptosis; Bone marrow adipocyte; Bone metastasis; Lipids; Metabolism; Survival
Authors: Guenter Haemmerle; Achim Lass; Robert Zimmermann; Gregor Gorkiewicz; Carola Meyer; Jan Rozman; Gerhard Heldmaier; Robert Maier; Christian Theussl; Sandra Eder; Dagmar Kratky; Erwin F Wagner; Martin Klingenspor; Gerald Hoefler; Rudolf Zechner Journal: Science Date: 2006-05-05 Impact factor: 47.728
Authors: Guenter Haemmerle; Tarek Moustafa; Gerald Woelkart; Sabrina Büttner; Albrecht Schmidt; Tineke van de Weijer; Matthijs Hesselink; Doris Jaeger; Petra C Kienesberger; Kathrin Zierler; Renate Schreiber; Thomas Eichmann; Dagmar Kolb; Petra Kotzbeck; Martina Schweiger; Manju Kumari; Sandra Eder; Gabriele Schoiswohl; Nuttaporn Wongsiriroj; Nina M Pollak; Franz P W Radner; Karina Preiss-Landl; Thomas Kolbe; Thomas Rülicke; Burkert Pieske; Michael Trauner; Achim Lass; Robert Zimmermann; Gerald Hoefler; Saverio Cinti; Erin E Kershaw; Patrick Schrauwen; Frank Madeo; Bernd Mayer; Rudolf Zechner Journal: Nat Med Date: 2011-08-21 Impact factor: 87.241
Authors: Lorenz C Hofbauer; Aline Bozec; Martina Rauner; Franz Jakob; Sven Perner; Klaus Pantel Journal: Nat Rev Clin Oncol Date: 2021-04-19 Impact factor: 66.675
Authors: Kerensa M Beekman; Martine Regenboog; Aart J Nederveen; Nathalie Bravenboer; Martin den Heijer; Peter H Bisschop; Carla E Hollak; Erik M Akkerman; Mario Maas Journal: Front Endocrinol (Lausanne) Date: 2022-04-27 Impact factor: 6.055
Authors: Ezequiel Monferrer; Isaac Vieco-Martí; Amparo López-Carrasco; Fernando Fariñas; Sergio Abanades; Luis de la Cruz-Merino; Rosa Noguera; Tomás Álvaro Naranjo Journal: Metabolites Date: 2021-04-23
Authors: Mackenzie K Herroon; Jonathan D Diedrich; Erandi Rajagurubandara; Carly Martin; Krishna R Maddipati; Seongho Kim; Elisabeth I Heath; James Granneman; Izabela Podgorski Journal: Mol Cancer Res Date: 2019-09-27 Impact factor: 5.852